First Time Loading...
A

Aquestive Therapeutics Inc
NASDAQ:AQST

Watchlist Manager
Aquestive Therapeutics Inc
NASDAQ:AQST
Watchlist
Price: 4.26 USD 3.9% Market Closed
Updated: Mar 29, 2024

Intrinsic Value

AQST's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. [ Read More ]

The intrinsic value of one AQST stock under the Base Case scenario is 2.47 USD. Compared to the current market price of 4.26 USD, Aquestive Therapeutics Inc is Overvalued by 42%.

Key Points:
AQST Intrinsic Value
Base Case
2.47 USD
Overvaluation 42%
Intrinsic Value
Price
A
Worst Case
Base Case
Best Case

Valuation Backtest
Aquestive Therapeutics Inc

Backtest AQST Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling AQST stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Aquestive Refinances Debt, Increases Revenue
2023-Q4 Earnings Call

Aquestive Refinances Debt, Increases Revenue

Aquestive Therapeutics strengthened its financial position by renegotiating a $45 million debt refinancing deal with a 13.5% interest rate, which reduced near-term cash requirements and eliminated revenue or cash covenants and stock purchase warrants. This was paired with significant revenue growth, as Q4 2023 revenues rose to $13.2 million, a 24% increase compared to Q4 2022. The full-year 2023 revenues climbed 26% to $50.6 million, excluding prior year sales of Sympazan. The net loss decreased to $8.1 million in Q4 2023, improving from $12.4 million in Q4 2022. The guidance for 2024 sets revenue targets between $48 million and $51 million but does not include any sales from Libervant.

Financials

Balance Sheet Decomposition
Aquestive Therapeutics Inc

Current Assets 41m
Cash & Short-Term Investments 23.9m
Receivables 8.5m
Other Current Assets 8.6m
Non-Current Assets 16.5m
PP&E 9.7m
Intangibles 1.3m
Other Non-Current Assets 5.4m
Current Liabilities 18.3m
Accounts Payable 8.9m
Accrued Liabilities 6.9m
Other Current Liabilities 2.5m
Non-Current Liabilities 145.6m
Long-Term Debt 27.5m
Other Non-Current Liabilities 118.1m
Efficiency

Earnings Waterfall
Aquestive Therapeutics Inc

Revenue
50.6m USD
Cost of Revenue
-20.8m USD
Gross Profit
29.8m USD
Operating Expenses
-44.9m USD
Operating Income
-15.1m USD
Other Expenses
7.2m USD
Net Income
-7.9m USD

Free Cash Flow Analysis
Aquestive Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

AQST Profitability Score
Profitability Due Diligence

Aquestive Therapeutics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Positive Gross Profit
ROIC is Increasing
Positive Revenue Growth Forecast
42/100
Profitability
Score

Aquestive Therapeutics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.

AQST Solvency Score
Solvency Due Diligence

Aquestive Therapeutics Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Positive Net Debt
Long-Term Solvency
34/100
Solvency
Score

Aquestive Therapeutics Inc's solvency score is 34/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AQST Price Targets Summary
Aquestive Therapeutics Inc

Wall Street analysts forecast AQST stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AQST is 8.16 USD with a low forecast of 6.06 USD and a high forecast of 10.5 USD.

Lowest
Price Target
6.06 USD
42% Upside
Average
Price Target
8.16 USD
92% Upside
Highest
Price Target
10.5 USD
146% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

AQST Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

AQST Price
Aquestive Therapeutics Inc

1M 1M
+16%
6M 6M
+178%
1Y 1Y
+326%
3Y 3Y
+2%
5Y 5Y
-38%
10Y 10Y
-73%
Annual Price Range
4.26
52w Low
1
52w High
6.09
Price Metrics
Average Annual Return -30.71%
Standard Deviation of Annual Returns 32.71%
Max Drawdown -93%
Shares Statistics
Market Capitalization 292m USD
Shares Outstanding 73 301 200
Percentage of Shares Shorted 3.38%

AQST Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Aquestive Therapeutics Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

292m USD

Dividend Yield

0%

Description

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 157 full-time employees. The company went IPO on 2018-07-25. The firm is engaged in developing orally administered products to deliver molecules, providing alternatives to care therapies. The company is engaged in advancing a late-stage product pipeline focused on treating diseases of the central nervous system (CNS), and an earlier stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. The firm's CNS portfolio, which is focused on epilepsy includes Sympazan and Libervant. The active programs in its complex molecule pipeline portfolio are: AQST-109-SF, AQST-108-SF, and AQST-108-SF. Its PharmFilm technology develops medicines that offer non-invasive delivery, customized suitability for patients with dysphagia, or trouble swallowing, can be administered without water and ensures consistent therapeutic dosing. PharmFilm is comprised of polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs) and excipients in place.

Contact

NEW JERSEY
WARREN
30 Technology Dr
+19089411900.0
https://aquestive.com/

IPO

2018-07-25

Employees

157

Officers

CEO, President & Director
Mr. Daniel Barber
Chief Innovation & Technology Officer
Mr. Alexander Mark Schobel
Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary
Ms. Lori J. Braender BSBA, Esq., J.D.
Chief Financial Officer
Mr. A. Ernest Toth Jr.
Senior Vice President of Operations
Ms. Cassie Jung
Senior Vice President of IT, HR & Communications
Mr. Peter E. Boyd
Show More
Senior VP of Research & Development
Dr. Stephen Wargacki
Chief Medical Officer
Dr. Carl N. Kraus M.D.
VP of Finance, Controller & Assistant Secretary
Mr. Robert Charles Arnold
Show Less

See Also

Discover More
What is the Intrinsic Value of one AQST stock?

The intrinsic value of one AQST stock under the Base Case scenario is 2.47 USD.

Is AQST stock undervalued or overvalued?

Compared to the current market price of 4.26 USD, Aquestive Therapeutics Inc is Overvalued by 42%.